SCHEMBL10160904

SCHEMBL10160904

CCc1ccc(-c2nnc(O)s2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.43
MGAM O43451 1/20 0.43
SI P14410 1/20 0.43
MGAM2 Q2M2H8 1/20 0.43
EGFR P00533 1/20 0.43
RAB9A P51151 5/20 0.42
KDM4E B2RXH2 5/20 0.42
SNCA P37840 1/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
TP53 P04637 3/20 0.41
NPC1 O15118 3/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.40
HSD17B10 Q99714 1/20 0.40
POLB P06746 1/20 0.40
ALDH1A1 P00352 3/20 0.39
LMNA P02545 2/20 0.39
HPGD P15428 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10131140 0.80 NR1H4 (0.40) GAAMGAMSIMGAM2RAB9A
SCHEMBL23329317 0.78 SMN1; SMN2 (0.46) GAARAB9AKDM4ESMN1; SMN2TP53
SCHEMBL10162561 0.78 NPC1 (0.44) GAARAB9AKDM4ESMN1; SMN2TP53
SCHEMBL10163324 0.77 KDM4E (0.68) GAAMGAMSIMGAM2RAB9A
SCHEMBL818881 0.75 ALDH1A1 (0.52) GAAMGAMSIMGAM2RAB9A
SCHEMBL9704090 0.74 RAB9A (0.47) GAARAB9AKDM4ESMN1; SMN2TP53
SCHEMBL9702825 0.74 RAB9A (0.47) GAARAB9AKDM4ESMN1; SMN2TP53
SCHEMBL9704789 0.74 RAB9A (0.47) GAARAB9AKDM4ESMN1; SMN2TP53
SCHEMBL9702454 0.73 RAB9A (0.54) GAARAB9AKDM4ESMN1; SMN2TP53
SCHEMBL9198575 0.72 GAA (0.55) GAAMGAMSIMGAM2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140135485-A1 6-11 BICYCLIC KETOLIDE DERIVATIVES ENANTA PHARMACEUTICALS, INC. (US) 2014-05-15 US disclosed
US-20120035352-A1 6-11 Bicyclic Ketolide Derivatives OR YAT SUN (US) 2012-02-09 US disclosed
EP-1506214-B1 6-11 BICYCLIC KETOLIDE DERIVATIVES ENANTA PHARM INC (US) 2010-01-20 EP disclosed
US-20090324577-A1 6-11 Bicyclic Ketolide Derivatives OR YAT SUN 2009-12-31 US disclosed
US-20070244160-A1 6-11 Bicyclic Ketolide Derivatives OR YAT SUN 2007-10-18 US disclosed
US-7189704-B2 6-11 bicyclic ketolide derivatives ENANTA PHARMACEUTICALS, INC. (US) 2007-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140135485-A1 6-11 BICYCLIC KETOLIDE DERIVATIVES AKR1C2, AKR1C3, AKR1C1 GAA 572/4885MGAM 75/4885SI 10/4885
US-20120035352-A1 6-11 Bicyclic Ketolide Derivatives AKR1C2, AKR1C3, AKR1C1 GAA 572/4885MGAM 75/4885SI 10/4885
US-20070244160-A1 6-11 Bicyclic Ketolide Derivatives AKR1C2, AKR1C3, AKR1C1 GAA 572/4885MGAM 75/4885SI 10/4885
US-20090324577-A1 6-11 Bicyclic Ketolide Derivatives AKR1C2, AKR1C3, AKR1C1 GAA 572/4885MGAM 75/4885SI 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.